On November 1, 2023 Anaveon, a clinical stage, immuno-oncology company, reported that it will present a poster on ANV600 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) being held from Friday, November 3, 2023, to Sunday, November 5, 2023, in San Diego, California (Press release, Anaveon, NOV 1, 2023, View Source [SID1234636622]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Targeting of stimulatory cytokines to PD-1 expressing tumor infiltrating lymphocytes (TILs) is a promising approach to reinvigorate antitumor immune responses. Currently, PD-1 checkpoint inhibitors (CPIs) have been established as the standard of care for many cancer indications. ANV600 combines a unique non-blocking PD-1 targeting approach with an IL-2Rβ/γ selective agonistic principle. This is a first example of a PD-1 targeted cytokine agonist which enables therapeutic combination of existing PD-1 inhibitors with novel PD-1 directed stimulatory cytokines.

"ANV600 is a powerful, new, targeted bispecific capable of proliferating tumor specific TILs" said Christoph Huber, Chief Scientific Officer of Anaveon. "We have designed the molecule to be compatible with anti-PD-1 antibodies to allow for optimal therapeutic combination of these agents."

The abstract is available on the SITC (Free SITC Whitepaper) website, and the accompanying poster will be on display on the Anaveon website on November 4, 10:00 am PDT.

Details of the poster presentation:

November 4, 9:00 am – 8:30 pm PDT, Poster #820

Title: ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

Authors: P. Murer, U. Salazar, N. Egli, L. Petersen, P. Neubert, Ch. Stocker, A. Rau, K. Richter, A. Katopodis and Ch. Huber

Anaveon is developing selective cytokine receptor agonists with the potential to therapeutically enhance a patient’s immune system to respond to tumors. ANV419, currently in Ph II studies in multiple cancer indications, is designed to preferentially signal through the IL-2 beta/gamma receptor resulting in strong proliferation of effector cells in patients. The follow-on compound, ANV600, targets the selective IL-2 receptor moiety to intratumoral effector cells and may have therapeutic benefit in less immunogenic tumors. These novel types of therapeutics, if approved, could potentially have a wide utility in oncology, including in combination with checkpoint inhibitors, cell therapies, vaccines, and radiotherapy.

On November 1, 2023 AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, reported that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team are scheduled to participate in multiple upcoming investor conferences in November (Press release, AnaptysBio, NOV 1, 2023, View Source [SID1234636621]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Conference Details

Guggenheim 5th Annual I&I Conference, New York, NY

Format – Fireside chat and one-on-one investor meetings
Date and Time – Tuesday, Nov. 7, 2023 at 9:50am ET / 6:50am PT
UBS Biopharma Conference 2023, Miami, FL

Format – One-on-one investor meetings
Date – Wednesday, Nov. 8, 2023
Stifel 2023 Healthcare Conference, New York, NY

Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Nov. 15, 2023 at 12:40pm ET / 9:40am PT
Piper Sandler 35th Annual Healthcare Conference, New York, NY

Format – Fireside chat and one-on-one investor meetings
Date and Time – Wednesday, Nov. 29, 2023 at 2:00pm ET / 11:00am PT
Evercore ISI 6th Annual HealthCONx Conference, Miami, FL

Format – Fireside chat and one-on-one investor meetings
Date and Time – Thursday, Nov. 30, 2023 at 10:25am ET / 7:25am PT
Live webcasts of the fireside chats will be available on the investor section of the Anaptys website at View Source Replays of the webcasts will be available for at least 30 days following the events.

On November 1, 2023 ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, reported that management will participate in three upcoming investor conferences in November (Press release, ALX Oncology, NOV 1, 2023, View Source [SID1234636620]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2023 UBS BioPharma Conference
Format: Fireside chat with analyst, Dr. Colin Bristow
Date: Wednesday, November 8th
Time: 1:30 PM EST
Location: Miami Beach, FL
Webcast link: Available here

2023 Jefferies London Healthcare Conference
Format: Fireside chat with analyst, Michael Yee
Date: Tuesday, November 14th
Time: 3:00 PM GMT
Location: London, UK
Webcast link: Available here

2023 Piper Sandler Healthcare Conference
Format: Fireside chat with analyst, Christopher Raymond
Date: Tuesday, November 28th
Time: 4:30 PM EST
Location: New York, NY
Webcast link: Available here

The live webcasts for the UBS, Jefferies and Piper Sandler fireside chats can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com and selecting Events under the News and Events tab. A replay of the webcast will be archived for up to 90 days following the fireside chat date.

On November 1, 2023 Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, reported that the Company will participate in a fireside chat at the TD Cowen 7th Annual Fall Oncology Innovation Summit on Friday, November 3, 2023 at 9:00 a.m. ET (Press release, Molecular Partners, NOV 1, 2023, View Source [SID1234636569]). Presenting on behalf of Molecular Partners will be Patrick Amstutz, Chief Executive Officer, and Dr. Philippe Legenne, acting CMO.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the event will be available on the "News and Events" page in the "Events" section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days following the presentation date.

On November 1, 2023 AstraZeneca reported a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases (Press release, AstraZeneca, NOV 1, 2023, View Source [SID1234636568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the collaboration agreement, AstraZeneca will leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to design novel cell and gene therapy products, strengthening AstraZeneca’s growing offering in this space. As part of the agreement, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 candidate products could be explored for development.

Marc Dunoyer, Chief Strategy Officer, AstraZeneca, and Chief Executive Officer, Alexion, AstraZeneca Rare Disease, said: "The differentiated capabilities Cellectis has in gene editing and manufacturing complement our in-house expertise and investments made in the past year. AstraZeneca continues to advance our ambition in cell therapy for oncology and autoimmune diseases as well as in genomic medicine, which has potential to be transformative for patients with rare diseases."

André Choulika, PhD, Chief Executive Officer of Cellectis, said: "We believe AstraZeneca is the perfect match to Cellectis by providing world-class expertise in the development and the commercialisation of innovative medicines. This collaboration will allow us to leverage our pioneering research in gene editing and cell therapies, as well as our cutting-edge capabilities in manufacturing with the ambition to bring potentially life-saving therapies to patients with unmet medical need."

Building on AstraZeneca’s own expertise in cell and genomic therapy, the Company has enhanced its capabilities through several collaborations and investments in the past year as part of its ambition to bring cell therapies to more patients living with cancer and to advance genomic medicines for rare diseases.

Financial considerations
In Q4 2023, Cellectis will receive an initial payment of $105m from AstraZeneca, which comprises a $25m upfront cash payment under the terms of a research collaboration agreement and an $80m equity investment.

The initial equity investment of $80m, at $5/share, represents an equity stake of c. 22% in Cellectis. A further $140m equity investment, at $5/share, is expected to close in early 2024 subject to the signing of a final binding agreement following completion of a consultation with the Cellectis employee representative bodies and customary closing conditions including Cellectis shareholders’ approval and regulatory clearances. Post-closing of this second investment, AstraZeneca will hold a total equity stake of c. 44% in Cellectis. AstraZeneca expects to treat its investment in Cellectis as an associate.

Under the terms of the research collaboration, Cellectis is also eligible to receive an investigational new drug (IND) option fee and development, regulatory and sales-related milestone payments, ranging from $70m up to $220m, per each of the 10 candidate products, plus tiered royalties.

AstraZeneca retains an option for a worldwide exclusive license for the candidate products developed under the research collaboration agreement, to be exercised before IND filing.